0001841401-22-000004.txt : 20221201
0001841401-22-000004.hdr.sgml : 20221201
20221201195851
ACCESSION NUMBER: 0001841401-22-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221129
FILED AS OF DATE: 20221201
DATE AS OF CHANGE: 20221201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wahl Bryan
CENTRAL INDEX KEY: 0001841401
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39614
FILM NUMBER: 221440019
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD, SUITE 160
CITY: IRVINE
STATE: CA
ZIP: 92618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001819790
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 814717861
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: (949) 409-9820
MAIL ADDRESS:
STREET 1: 15440 LAGUNA CANYON ROAD
CITY: IRVINE
STATE: CA
ZIP: 92618
4
1
wf-form4_166994271203193.xml
FORM 4
X0306
4
2022-11-29
0
0001819790
Tarsus Pharmaceuticals, Inc.
TARS
0001841401
Wahl Bryan
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE
CA
92618
0
1
0
0
General Counsel
Common Stock
2022-11-29
4
M
0
10251
0
A
17224
D
Common Stock
2022-11-30
4
S
0
1183
16.50
D
16041
D
Common Stock
2022-12-01
4
S
0
1164
16.75
D
14877
D
Restricted Stock Units
2022-11-29
4
M
0
10251
0
D
Common Stock
10251.0
23920
D
The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2022.
Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
RSU granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest 30% on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service.
/s/ Leonard M. Greenstein, Attorney-in-Fact
2022-12-01